Literature DB >> 7468684

Pelvic inflammatory disease and puerperal sepsis in Ethiopia. I. Etiology.

P L Perine, M E Duncan, D W Krause, S Awoke.   

Abstract

Among 100 outpatient women with symptoms and signs of pelvic inflammatory disease and 200 asymptomatic, postpartum women, the prevalence rates of Neisseria gonorrhoeae were 19% and 9%, respectively. Of 46 women hospitalized for PID, 33% were culture-negative, 22% grew Enterobacteriaceae, 20% grew streptococci, 15% grew gonococci, and 15% grew anaerobes from blood, pus, or abscesses. One third of 67 women hospitalized for puerperal sepsis (PPS) were culture-negative; the bacteria isolated most frequently from the uterus, blood, urine, and pus were Enterobacteriaceae (36%), gonococci (28%), streptococci (25%), and anaerobes (4%). The low frequency of isolation of anaerobes in women with PID and PPS was due largely to limitations placed on the collection and processing of specimens for anaerobic bacteriology.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7468684     DOI: 10.1016/0002-9378(80)91089-3

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  4 in total

1.  Is there a critical time for prophylaxis against neonatal gonococcal ophthalmia?

Authors:  L Muhe; N Tafari
Journal:  Genitourin Med       Date:  1986-10

2.  Evaluation of a serum gonococcal antibody test.

Authors:  L Grubin; N G Osborne
Journal:  J Natl Med Assoc       Date:  1985-11       Impact factor: 1.798

3.  Seroepidemiological study of gonorrhoea in Ethiopian women. 1. Prevalence and clinical significance.

Authors:  M E Duncan; K Reimann; G Tibaux; A Pelzer; L Mehari; I Lind
Journal:  Genitourin Med       Date:  1991-12

Review 4.  Maternal and early onset neonatal bacterial sepsis: burden and strategies for prevention in sub-Saharan Africa.

Authors:  Anna C Seale; Michael Mwaniki; Charles R J C Newton; James A Berkley
Journal:  Lancet Infect Dis       Date:  2009-07       Impact factor: 25.071

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.